Verrica Pharmaceuticals receives permanent J-Code for YCANTH from CMS

Verrica Pharmaceuticals announced that the Centers for Medicare & Medicaid Services, CMS, has issued a permanent J-Code for YCANTH, which is the only FDA-approved treatment for molluscum contagiosum. Under the Healthcare Common Procedure Coding System, HCPCS, process, the J-Code for YCANTH will become fully published April 1, 2024. “By securing a permanent J-Code for YCANTH, we have successfully reached a critical milestone in our commercial strategy that we expect will help us accelerate YCANTH utilization among the U.S. Medicaid and Medicare patient populations,” said Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals. “In addition to greater patient access, we also anticipate a permanent J-Code will result in a more streamlined billing and reimbursement process for YCANTH.”